首页> 外文期刊>Science >Genetic identification of familial hypercholesterolemia within a single US health care system
【24h】

Genetic identification of familial hypercholesterolemia within a single US health care system

机译:单一美国卫生保健系统中家族性高胆固醇血症的遗传鉴定

获取原文
获取原文并翻译 | 示例
       

摘要

Familial hypercholesterolemia (FH) remains underdiagnosed despite widespread cholesterol screening. Exome sequencing and electronic health record (EHR) data of 50,726 individuals were used to assess the prevalence and clinical impact of FH-associated genomic variants in the Geisinger Health System. The estimated FH prevalence was 1: 256 in unselected participants and 1: 118 in participants ascertained via the cardiac catheterization laboratory. FH variant carriers had significantly increased risk of coronary artery disease. Only 24% of carriers met EHR-based presequencing criteria for probable or definite FH diagnosis. Active statin use was identified in 58% of carriers; 46% of statin-treated carriers had a low-density lipoprotein cholesterol level below 100 mg/dl. Thus, we find that genomic screening can prompt the diagnosis of FH patients, most of whom are receiving inadequate lipid-lowering therapy.
机译:尽管进行了广泛的胆固醇筛查,但家族性高胆固醇血症(FH)仍未得到充分诊断。使用50,726个人的外显子组测序和电子健康记录(EHR)数据评估了Geisinger Health System中与FH相关的基因组变异的患病率和临床影响。通过心脏导管实验室确定的未选参与者中,估计的FH患病率为1:256,参与者中为1:118。 FH变异携带者显着增加了冠状​​动脉疾病的风险。只有24%的携带者满足了基于EHR的可能或确定的FH诊断的预先排序标准。在58%的携带者中发现积极使用他汀类药物;他汀类药物治疗的载体中有46%的低密度脂蛋白胆固醇水平低于100 mg / dl。因此,我们发现基因组筛查可以促进FH患者的诊断,其中大多数患者接受的降脂治疗不足。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号